Objective Ovarian cancer is associated with the highest mortality rate among all malignant gynecological tumors. PolyADP-ribose polymerase (PARP) inhibitor maintenance therapy is the standard treatment strategy for this type of cancer, and olaparib is a widely used oral PARP inhibitor for tumors with BRCA mutations. The present study aimed to investigate the effects of olaparib in non-BRCA-mutated ovarian cancer and the potential mechanisms involved. Methods The antitumor effect of cisplatin alone or in combination with olaparib was analyzed in an ovarian cancer subcutaneous transplantation tumor model in nude mice. Furthermore, the differences in microRNA (miRNA) expression levels were analyzed using miRNA arrays. In addition, the effects of miR-125a-3p on the proliferation of non-BRCA-mutated (A2780 and OVCAR-3) ovarian cancer cells were detected using A Cell Counting Kit-8 and changes in the cell cycle were detected using flow cytometry. Furthermore, SPiDER-βGal was used to detect expression changes in cellular senescence, and the expression of DNA damage repair proteins was detected using western blot analysis. Results The results revealed that cisplatin plus olaparib significantly reduced tumor volume in mice subjected to subcutaneous tumor transplantation, and the expression of miR-125a-3p significantly increased with this treatment combination. The overexpression of miR-125a-3p could inhibit cell migration, invasion and induces cell cycle arrest. Conclusion On the whole, the present study demonstrates that the increased expression of miR-125a-3p induces DNA damage and senescence in ovarian cancer cells, which enhances the therapeutic sensitivity.
14 October 2026 in Journal for ImmunoTherapy of Cancer
Homologous recombination deficiency (HRD) in high-grade serous ovarian carcinoma (HGSOC) canonically dictates sensitivity to platinum chemotherapy and poly(ADP-ribose) polymerase inhibitors. Although CCNE1 amplification is generally mutually exclusive with BRCA mutations, CCNE1 overexpression paradoxically co-occurs with HRD in approximately 4%–12% of cases. We investigated the clinical impact and immune landscape of this concurrent phenotype to uncover novel therapeutic vulnerabilities. We stratified HGSOC patients from independent cohorts based on CCNE1 expression and HRD status to evaluate survival and therapeutic response. The tumor immune microenvironment was characterized using single-cell RNA sequencing and multiplex immunofluorescence. Mechanistic investigations were conducted using Brca1-deficient ID8 murine models, and the efficacy of anti-PD-1 therapy was assessed in vivo and ex vivo using the patient-derived tumor fragments (PDTFs) platform. Clinically, CCNE1 overexpression abrogated the survival advantage typically conferred by HRD. Biologically, however, CCNE1high/HRD tumors exhibited a highly inflamed microenvironment characterized by robust infiltration of polyfunctional CD8+ T cells and CXCL9+ tumor-associated macrophages. Mechanistically, CCNE1 overexpression in an HRD background exacerbated replication stress and reactive oxygen species (ROS) accumulation, leading to cytosolic DNA leakage. This triggered a cGAS–STING-dependent type I interferon response, which was reversed by STING inhibition or ROS scavengers. Consequently, CCNE1high/HRD tumors demonstrated profound sensitivity to anti-PD-1 treatment in syngeneic mouse models and the HGSOC PDTFs platform. CCNE1 overexpression in HRD ovarian cancer drives cGAS–STING-dependent inflammation, transforming genotoxin-refractory tumors into highly vulnerable targets for anti-PD-1 therapy.